X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5633) 5633
Newsletter (304) 304
Book Chapter (42) 42
Newspaper Article (39) 39
Dissertation (13) 13
Publication (8) 8
Conference Proceeding (6) 6
Magazine Article (6) 6
Reference (2) 2
Book / eBook (1) 1
Book Review (1) 1
Government Document (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3967) 3967
science & technology (3759) 3759
erlotinib (3732) 3732
life sciences & biomedicine (3575) 3575
erlotinib hydrochloride (2723) 2723
oncology (2520) 2520
lung neoplasms - drug therapy (2082) 2082
female (1923) 1923
carcinoma, non-small-cell lung - drug therapy (1767) 1767
male (1689) 1689
quinazolines - therapeutic use (1474) 1474
middle aged (1454) 1454
receptor, epidermal growth factor - antagonists & inhibitors (1391) 1391
aged (1338) 1338
protein kinase inhibitors - therapeutic use (1191) 1191
cancer (1182) 1182
lung cancer, non-small cell (1117) 1117
antineoplastic agents - therapeutic use (1091) 1091
mutation (995) 995
gefitinib (987) 987
lung neoplasms - pathology (985) 985
adult (947) 947
lung cancer (937) 937
care and treatment (934) 934
receptor, epidermal growth factor - genetics (912) 912
epidermal growth factor (911) 911
lung neoplasms - genetics (886) 886
treatment outcome (841) 841
quinazolines - administration & dosage (836) 836
research (824) 824
antineoplastic combined chemotherapy protocols - therapeutic use (754) 754
carcinoma, non-small-cell lung - pathology (753) 753
quinazolines - pharmacology (745) 745
animals (722) 722
chemotherapy (720) 720
cell line, tumor (706) 706
carcinoma, non-small-cell lung - genetics (705) 705
quinazolines - adverse effects (660) 660
aged, 80 and over (632) 632
egfr (615) 615
protein kinase inhibitors - pharmacology (613) 613
respiratory tract diseases (596) 596
non-small cell lung cancer (593) 593
receptor, epidermal growth factor - metabolism (553) 553
epidermal growth factor receptor (538) 538
antineoplastic agents - pharmacology (512) 512
analysis (506) 506
respiratory system (489) 489
pharmacology & pharmacy (488) 488
tyrosine (484) 484
adenocarcinoma - drug therapy (483) 483
disease-free survival (473) 473
mice (471) 471
drug therapy (462) 462
cetuximab (441) 441
erlotinib hydrochloride - therapeutic use (436) 436
neoplasm staging (430) 430
bevacizumab (419) 419
hematology, oncology and palliative medicine (418) 418
protein kinase inhibitors - adverse effects (413) 413
prognosis (400) 400
lung neoplasms - mortality (378) 378
metastasis (371) 371
neoplasms (366) 366
health aspects (359) 359
carcinoma, non-small-cell lung - mortality (347) 347
protein kinase inhibitors - administration & dosage (343) 343
antineoplastic agents - adverse effects (342) 342
antibodies, monoclonal, humanized (341) 341
genetic aspects (339) 339
nsclc (339) 339
erlotinib hydrochloride - administration & dosage (338) 338
oncology, experimental (330) 330
lung neoplasms - metabolism (326) 326
clinical trials (323) 323
pancreatic cancer (322) 322
erlotinib hydrochloride - pharmacology (318) 318
erbb receptors - antagonists & inhibitors (308) 308
medicine & public health (306) 306
tumors (304) 304
deoxycytidine - analogs & derivatives (300) 300
cancer therapies (299) 299
kinases (298) 298
drug resistance, neoplasm (295) 295
erbb receptors - genetics (287) 287
lung cancer, small cell (285) 285
retrospective studies (284) 284
antineoplastic agents - administration & dosage (279) 279
survival rate (278) 278
pulmonary/respiratory (275) 275
cell proliferation - drug effects (270) 270
pancreatic neoplasms - drug therapy (267) 267
epidermal growth factor receptors (260) 260
dosage and administration (258) 258
antibodies, monoclonal - therapeutic use (255) 255
carcinoma, non-small-cell lung - metabolism (250) 250
signal transduction - drug effects (248) 248
survival analysis (247) 247
patients (242) 242
disease progression (241) 241
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5691) 5691
French (114) 114
Chinese (92) 92
Japanese (59) 59
German (58) 58
Korean (37) 37
Spanish (34) 34
Portuguese (22) 22
Czech (11) 11
Hungarian (10) 10
Russian (8) 8
Polish (6) 6
Turkish (6) 6
Dutch (5) 5
Italian (4) 4
Danish (3) 3
Norwegian (2) 2
Croatian (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European journal of cancer (1990), ISSN 0959-8049, 03/2016, Volume 55, pp. 131 - 139
Abstract Aim The aim of this study was to investigate if biomarkers of individual drug metabolism, respectively, the erlotinib/O-desmethyl-erlotinib metabolic... 
Hematology, Oncology and Palliative Medicine | Erlotinib/O-desmethyl-erlotinib ratio | EGFR inhibitor-induced skin rash | Erlotinib metabolic ratio | Predictive biomarker | Life Sciences & Biomedicine | Oncology | Science & Technology | Exanthema - diagnosis | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Drug Monitoring - methods | Protein Kinase Inhibitors - adverse effects | Exanthema - chemically induced | Aged, 80 and over | Antineoplastic Agents - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Erlotinib Hydrochloride - adverse effects | Lung Neoplasms - enzymology | Erlotinib Hydrochloride - pharmacokinetics | Adenocarcinoma - blood | Pancreatic Neoplasms - pathology | Adenocarcinoma - drug therapy | Disease Progression | Protein Kinase Inhibitors - blood | Erlotinib Hydrochloride - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Carcinoma, Non-Small-Cell Lung - enzymology | Germany | Lung Neoplasms - pathology | Pancreatic Neoplasms - drug therapy | Drug Dosage Calculations | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Biotransformation | Adult | Female | Pancreatic Neoplasms - mortality | Carcinoma, Non-Small-Cell Lung - pathology | Severity of Illness Index | Pancreatic Neoplasms - blood | Dealkylation | Adenocarcinoma - enzymology | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Pancreatic Neoplasms - enzymology | Proportional Hazards Models | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - blood | Aged | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Epidermal growth factor | Erlotinib | Skin care products | Physiological aspects | Rash (Dermatology) | Skin | Biological markers | Index Medicus
Journal Article
Journal of controlled release, ISSN 0168-3659, 05/2016, Volume 229, pp. 80 - 92
Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize... 
pH-sensitive | Charge conversion | MSN | Erlotinib | DOX | Synergistic therapy | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Doxorubicin - therapeutic use | Drug Carriers - therapeutic use | Nanoparticles - chemistry | Apoptosis - drug effects | Benzoates - chemistry | Humans | Erlotinib Hydrochloride - chemistry | Drug Carriers - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Protein Kinase Inhibitors - chemistry | Nanoparticles - therapeutic use | Antineoplastic Agents - pharmacokinetics | Drug Therapy, Combination | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | A549 Cells | Cell Survival - drug effects | Erlotinib Hydrochloride - pharmacokinetics | Mice, Inbred C57BL | Erlotinib Hydrochloride - administration & dosage | Phosphatidylcholines - chemistry | Antineoplastic Agents - chemistry | Rats, Sprague-Dawley | Doxorubicin - pharmacokinetics | Carcinoma, Lewis Lung - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Drug Liberation | Drug Carriers - pharmacokinetics | Erlotinib Hydrochloride - therapeutic use | Nanoparticles - administration & dosage | Hydrogen-Ion Concentration | Membrane lipids | Anthracyclines | Epidermal growth factor | Hydrogen-ion concentration | Lung cancer | Surface active agents | Drug discovery | Index Medicus
Journal Article
Journal Article
by Wu, Y.-L and Zhou, C and Liam, C.-K and Wu, G and Liu, X and Zhong, Z and Lu, S and Cheng, Y and Han, B and Chen, L and Huang, C and Qin, S and Zhu, Y and Pan, H and Liang, H and Li, E and Jiang, G and How, S.H and Fernando, M.C.L and Zhang, Y and Xia, F and Zuo, Y
Annals of oncology, ISSN 0923-7534, 09/2015, Volume 26, Issue 9, pp. 1883 - 1889
Journal Article
Journal of controlled release, ISSN 0168-3659, 01/2017, Volume 246, pp. 120 - 132
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2016, Volume 315, Issue 12, pp. 1266 - 1275
Journal Article
Molecular imaging and biology, ISSN 1860-2002, 10/2018, Volume 21, Issue 4, pp. 696 - 704
Journal Article